Key clinical point: Among patients with chronic migraine, the use of concomitant oral treatments (CT) with onabotulinumtoxinA (BoNTA) was not associated with any unexpected tolerability concerns; however, BoNTA plus CT specifically for migraine vs BoNTA alone led to lesser reduction in monthly headache days (MHD).
Major finding: The reduction in MHD after 2-4 cycles of BoNTA treatment was significantly lower among patients receiving BoNTA plus CT for migraine vs BoNTA alone ( P < .05). Side effects occurred in 20.3% of patients receiving BoNTA plus CT for migraine, with only 4.1% experiencing significant interference with functioning.
Study details: This retrospective study included 178 patients with chronic migraine who received prophylactic BoNTA with or without CT with a potential effect on migraine.
Disclosures: This study received only the open access funding enabled by Projekt DEAL. Several authors declared receiving honoraria and research funding, serving on advisory boards, or having other ties with various sources. Three authors, including the lead author, declared no conflicts of interest.
Source: Overeem LH et al. A retrospective real-life multicenter study on concurrent oral preventive treatments in patients with chronic migraine treated with onabotulinumtoxinA. CNS Drugs. 2023;37:453-465 (May 22). doi: 10.1007/s40263-023-01001-y